A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

NCT06130553 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

334

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors That Are MTAP Deficient

Interventions

DRUG: AZD3470
DRUG: Datopotamab deruxtecan

Sponsor

AstraZeneca